Skip to Content

Boston Scientific Corp BSX Stock Quote

| Rating as of

Morningstar‘s Stock Analysis BSX

Currency in USD
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Boston Scientific Poised to See Volume Growth as Pandemic Eases

Debbie S. Wang Senior Equity Analyst

Business Strategy and Outlook

| Debbie S. Wang |

Boston Scientific has solidified its footing as one of three major cardiac device makers and significantly improved its innovation and operational chops. We think the firm's ability to emerge strongly from nearly a decade of acquisition and management upheaval underscores just how tough a competitor Boston is as well as how difficult it is for any new competitors to establish a foothold in these highly consolidated device markets. Under CEO Michael Mahoney, the firm has focused on introducing meaningful innovation and leveraging its historically formidable sales and marketing resources.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics BSX

Company Profile BSX

Business Description

Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.

300 Boston Scientific Way
Marlborough, MA, 01752-1234
T +1 508 683-4000
Industry Medical Devices
Most Recent Earnings Jun 30, 2022
Fiscal Year End Dec 31, 2021
Employees 41,000

Related News BSX